YTENQ (Yield10 Bioscience) Accounts Payable & Accrued Expense : $3.52 Mil (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Accounts Payable & Accrued Expense?

Yield10 Bioscience's quarterly accounts payable & accrued expense declined from Dec. 2023 ($3.08 Mil) to Mar. 2024 ($2.40 Mil) but then increased from Mar. 2024 ($2.40 Mil) to Jun. 2024 ($3.52 Mil).

Yield10 Bioscience's annual accounts payable & accrued expense increased from Dec. 2021 ($0.70 Mil) to Dec. 2022 ($0.92 Mil) and increased from Dec. 2022 ($0.92 Mil) to Dec. 2023 ($3.08 Mil).

Yield10 Bioscience Accounts Payable & Accrued Expense Historical Data

The historical data trend for Yield10 Bioscience's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience Accounts Payable & Accrued Expense Chart

Yield10 Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.89

0.55

0.70

0.92

3.08

Yield10 Bioscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.51	1.85	3.08	2.40	3.52

Yield10 Bioscience Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Yield10 Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTENQ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Presidential Way, Woburn, MA, USA, 01801

Website

https://www.yield10bio.com

Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton	director	1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser	officer: VP Fin and CAO
Lynne H Brum	officer: VP Planning and Comms	21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell	officer: VP Research & CSO	C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey	director	C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples	director, officer: Pres & CEO	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin	director	21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully	10 percent owner	C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038